ProPhase Labs terminates $7.7M equity line with Keystone Capital Partners

ProPhase Labs, Inc.

Terminated Common Stock Purchase Agreement with Keystone Capital Partners effective August 28, 2025.
Agreement allowed sale of up to ~$7.7M of common stock at Company’s option.
Termination was at sole discretion, with no penalties or termination fees.
No other material relationships between Company and Keystone.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.